Abstract
CMT-3 is a NON-ANTIMICROBIAL tetracycline (TC), chemically modified to enhance its collagenase-inhibitory property. This property is therapeutically useful in treating diseases such as periodontitis, cancer and arthritis. CMT-3 was labeled with tritium ( 3 H) at Carbon 7. Four adult male Sprague-Dawley rats (350-400 g body weight) were gavaged once with a mixture of cold CMT-3 and ( 3 H) CMT-3 (750 mu Ci). An additional four rats were gavaged for 2 days with cold CMT-3(15 mg/Kg/day) and on the third day the rats were gavaged with a mixture of cold and (3 H) CMT-3 (750 mu Ci) and all 8 rats were placed in the metabolic cages. Blood samples were collected from the tail at multiple intervals from 1-14 hr after ( 3 H) CMT-3 administration. At 14 hr, the rats were anesthetized, euthanized and various tissues including visceral organs were removed and weighed. The contents of GI tracts were emptied and added to the fecal pellets and weighed. The urine samples were collected and volume measured. Each tissue or organ was minced finely with scissors and 100 mg of tissue was digested in 1 ml of Tissue-solv (Packard Lab), for 4 hrs at 37 o C and each sample was diluted up to 10 ml of distilled water. A 100 ml aliquot was taken and diluted with an equal volume of glacial acetic acid, 10 ml of Atom-lite was added and counted for radioactivity in a liquid scintillation spectrometer. This biodistribution study revealed that over 14 hrs, 54 percent and 3 percentof ( 3 H) CMT-3 were excreted in the feces and urine, respectively. The serum ( 3 H) CMT-3 count reached its maximum value at about 12 hours. The tissues retained the CMTs as follow: muscle (23percent); skin (2.41percent); bone (1.72percent); and the brain retained 0.21percent of the label. The radioactive CMT-3 in the visceral organs is as follows: GI tract - its contents (8.9percent); heart (0.41percent), testis (0.41percent); lungs greater than(0.16percent); spleen (0.08percent); liver (0.03percent); kidneys greater than (0.02percent).
Keywords: Radiolabeled CMT 3, Non antimicrobial tetracycline, experimental peridontitis, pharmacokinetics studies, CMT 3 administratio
Current Medicinal Chemistry
Title: Biodistribution of Radiolabeled [ 3 H] CMT-3 in Rats
Volume: 8 Issue: 3
Author(s): J. Chen, M. Bookbinder, M. E. Ryan, L. M. Golub, R. Ashley and N. S. Ramamurthy
Affiliation:
Keywords: Radiolabeled CMT 3, Non antimicrobial tetracycline, experimental peridontitis, pharmacokinetics studies, CMT 3 administratio
Abstract: CMT-3 is a NON-ANTIMICROBIAL tetracycline (TC), chemically modified to enhance its collagenase-inhibitory property. This property is therapeutically useful in treating diseases such as periodontitis, cancer and arthritis. CMT-3 was labeled with tritium ( 3 H) at Carbon 7. Four adult male Sprague-Dawley rats (350-400 g body weight) were gavaged once with a mixture of cold CMT-3 and ( 3 H) CMT-3 (750 mu Ci). An additional four rats were gavaged for 2 days with cold CMT-3(15 mg/Kg/day) and on the third day the rats were gavaged with a mixture of cold and (3 H) CMT-3 (750 mu Ci) and all 8 rats were placed in the metabolic cages. Blood samples were collected from the tail at multiple intervals from 1-14 hr after ( 3 H) CMT-3 administration. At 14 hr, the rats were anesthetized, euthanized and various tissues including visceral organs were removed and weighed. The contents of GI tracts were emptied and added to the fecal pellets and weighed. The urine samples were collected and volume measured. Each tissue or organ was minced finely with scissors and 100 mg of tissue was digested in 1 ml of Tissue-solv (Packard Lab), for 4 hrs at 37 o C and each sample was diluted up to 10 ml of distilled water. A 100 ml aliquot was taken and diluted with an equal volume of glacial acetic acid, 10 ml of Atom-lite was added and counted for radioactivity in a liquid scintillation spectrometer. This biodistribution study revealed that over 14 hrs, 54 percent and 3 percentof ( 3 H) CMT-3 were excreted in the feces and urine, respectively. The serum ( 3 H) CMT-3 count reached its maximum value at about 12 hours. The tissues retained the CMTs as follow: muscle (23percent); skin (2.41percent); bone (1.72percent); and the brain retained 0.21percent of the label. The radioactive CMT-3 in the visceral organs is as follows: GI tract - its contents (8.9percent); heart (0.41percent), testis (0.41percent); lungs greater than(0.16percent); spleen (0.08percent); liver (0.03percent); kidneys greater than (0.02percent).
Export Options
About this article
Cite this article as:
Chen J., Bookbinder M., Ryan E. M., Golub M. L., Ashley R. and Ramamurthy S. N., Biodistribution of Radiolabeled [ 3 H] CMT-3 in Rats, Current Medicinal Chemistry 2001; 8 (3) . https://dx.doi.org/10.2174/0929867013373615
DOI https://dx.doi.org/10.2174/0929867013373615 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index To Volume 3
Current Drug Delivery Identification and Characterization of Intraoral and Dermal Fibroblasts Revisited
Current Stem Cell Research & Therapy Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Mucoadhesive Chitosan Derivatives as Novel Drug Carriers
Current Pharmaceutical Design Applied Proteomics in Companion Animal Medicine
Current Proteomics Role of the Epithelial Cell Rests of Malassez in Periodontal Homeostasis and Regeneration - A Review
Current Stem Cell Research & Therapy MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Oral Candidosis in HIV-Infected Patients
Current HIV Research Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Role of Mesenchymal Stem Cells in Dermal Repair in Burns and Diabetic Wounds
Current Stem Cell Research & Therapy Hypothermicpreservation of Mouse Induced Pluripotent Stem Cells by Polyampholytes
Current Nanoscience Pathophysiology of Erectile Dysfunction
Current Drug Targets Clinical Pharmacokinetics of Ibuprofen Arginine
Current Clinical Pharmacology RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews Antimicrobial Efficacy of Extemporaneously Prepared Herbal Mouthwashes
Recent Patents on Drug Delivery & Formulation The Methylerythritol Phosphate Pathway and its Significance as a Novel Drug Target
Current Pharmaceutical Biotechnology Phytochemicals as Inhibitors of Candida Biofilm
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology